II期临床-话题@MedSci

#II期临床#

478篇内容 | 2602人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524727, encodeId=b1c71524e27fc, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, objectType=article, longId=177714, objectId=d4e41e7714e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4e41e7714e1, replyNumber=0, likeNumber=61, createdTime=2019-08-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4e41e7714e1, moduleTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4e41e7714e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524726, encodeId=5c801524e265e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, objectType=article, longId=177383, objectId=b6d81e73834c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6d81e73834c, replyNumber=0, likeNumber=62, createdTime=2019-08-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6d81e73834c, moduleTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6d81e73834c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524725, encodeId=06381524e25a5, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=维罗纳制药使用干粉吸入的恩替芬碱治疗慢性阻塞性肺病II期临床结果喜人, objectType=article, longId=177340, objectId=018c1e7340aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=018c1e7340aa, replyNumber=0, likeNumber=54, createdTime=2019-08-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=018c1e7340aa, moduleTitle=维罗纳制药使用干粉吸入的恩替芬碱治疗慢性阻塞性肺病II期临床结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=018c1e7340aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524724, encodeId=0cc91524e2476, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, objectType=article, longId=177339, objectId=a5a91e73396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5a91e73396a, replyNumber=0, likeNumber=73, createdTime=2019-08-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5a91e73396a, moduleTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5a91e73396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524723, encodeId=5b321524e23be, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点, objectType=article, longId=176549, objectId=9a1f1e654908, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a1f1e654908, replyNumber=0, likeNumber=102, createdTime=2019-08-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a1f1e654908, moduleTitle=斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a1f1e654908)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524722, encodeId=58001524e224f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Sanfilippo综合征A型的基因疗法：基因疗法ABO-102的I/II期临床试验取得阶段性成果, objectType=article, longId=176224, objectId=18291e622416, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18291e622416, replyNumber=0, likeNumber=94, createdTime=2019-07-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18291e622416, moduleTitle=Sanfilippo综合征A型的基因疗法：基因疗法ABO-102的I/II期临床试验取得阶段性成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18291e622416)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524721, encodeId=e1931524e21dd, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效, objectType=article, longId=175613, objectId=674d1e56136b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=674d1e56136b, replyNumber=0, likeNumber=15, createdTime=2019-07-18, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=674d1e56136b, moduleTitle=2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=674d1e56136b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524720, encodeId=6d371524e2003, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=青蒿素衍生物红斑狼疮候选新药进入II期临床, objectType=article, longId=175547, objectId=fa791e55472f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa791e55472f, replyNumber=0, likeNumber=71, createdTime=2019-07-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa791e55472f, moduleTitle=青蒿素衍生物红斑狼疮候选新药进入II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa791e55472f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524719, encodeId=29101524e1934, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=2019年国际血栓和止血学会：强生宣布抗凝剂Xarelto在儿科静脉血栓栓塞III期临床取得成功, objectType=article, longId=175120, objectId=15c11e51207f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15c11e51207f, replyNumber=0, likeNumber=57, createdTime=2019-07-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15c11e51207f, moduleTitle=2019年国际血栓和止血学会：强生宣布抗凝剂Xarelto在儿科静脉血栓栓塞III期临床取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15c11e51207f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524718, encodeId=1df91524e185f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, objectType=article, longId=174987, objectId=88ee1e49876f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88ee1e49876f, replyNumber=0, likeNumber=53, createdTime=2019-07-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88ee1e49876f, moduleTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88ee1e49876f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524717, encodeId=4d8e1524e17a9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ESMO世界胃肠癌大会：murlentamab的II期临床研究结果, objectType=article, longId=174985, objectId=0a901e49851b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a901e49851b, replyNumber=0, likeNumber=56, createdTime=2019-07-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a901e49851b, moduleTitle=ESMO世界胃肠癌大会：murlentamab的II期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a901e49851b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524716, encodeId=318a1524e1600, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, objectType=article, longId=174669, objectId=3b101e46693f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b101e46693f, replyNumber=0, likeNumber=59, createdTime=2019-07-03, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b101e46693f, moduleTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b101e46693f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524715, encodeId=06291524e1597, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, objectType=article, longId=174364, objectId=c1da1e436402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e436402, replyNumber=0, likeNumber=75, createdTime=2019-06-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e436402, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e436402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524714, encodeId=c7f81524e147b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症, objectType=article, longId=174342, objectId=3d2b1e4342ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d2b1e4342ca, replyNumber=0, likeNumber=62, createdTime=2019-06-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d2b1e4342ca, moduleTitle=FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d2b1e4342ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524713, encodeId=cda11524e13eb, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=斑蝥素治疗常见疣的II期临床研究取得积极成绩, objectType=article, longId=174339, objectId=2db21e433919, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2db21e433919, replyNumber=0, likeNumber=84, createdTime=2019-06-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2db21e433919, moduleTitle=斑蝥素治疗常见疣的II期临床研究取得积极成绩, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2db21e433919)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524712, encodeId=bf2b1524e128f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功, objectType=article, longId=172193, objectId=f8e41e2193df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8e41e2193df, replyNumber=0, likeNumber=62, createdTime=2019-06-27, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8e41e2193df, moduleTitle=赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8e41e2193df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524711, encodeId=cf5f1524e1103, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验, objectType=article, longId=168728, objectId=5792168e289d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5792168e289d, replyNumber=0, likeNumber=75, createdTime=2019-06-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5792168e289d, moduleTitle=第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5792168e289d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524710, encodeId=57301524e1056, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=国产艾滋病疫苗II期临床试验启动：1500元补助招志愿者, objectType=article, longId=168391, objectId=bfb4168391a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfb4168391a4, replyNumber=0, likeNumber=69, createdTime=2019-06-15, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfb4168391a4, moduleTitle=国产艾滋病疫苗II期临床试验启动：1500元补助招志愿者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfb4168391a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524709, encodeId=87121524e09dd, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=第79届ADA：Dance 501吸入型胰岛素的II期临床结果喜人, objectType=article, longId=167971, objectId=033116e97107, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=033116e97107, replyNumber=0, likeNumber=68, createdTime=2019-06-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=033116e97107, moduleTitle=第79届ADA：Dance 501吸入型胰岛素的II期临床结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=033116e97107)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524708, encodeId=04421524e081e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色, objectType=article, longId=167610, objectId=0be116e61073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0be116e61073, replyNumber=0, likeNumber=78, createdTime=2019-06-05, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0be116e61073, moduleTitle=2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0be116e61073)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功

2019-08-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率

2019-08-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

维罗纳制药使用干粉吸入的恩替芬碱治疗慢性阻塞性肺病II期临床结果喜人

2019-08-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功

2019-08-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点

2019-08-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Sanfilippo综合征A型的基因疗法：基因疗法ABO-102的I/II期临床试验取得阶段性成果

2019-07-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效

2019-07-18

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

青蒿素衍生物红斑狼疮候选新药进入II期临床

2019-07-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

2019年国际血栓和止血学会：强生宣布抗凝剂Xarelto在儿科静脉血栓栓塞III期临床取得成功

2019-07-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究

2019-07-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ESMO世界胃肠癌大会：murlentamab的II期临床研究结果

2019-07-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效

2019-07-03

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点

2019-06-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症

2019-06-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

斑蝥素治疗常见疣的II期临床研究取得积极成绩

2019-06-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功

2019-06-27

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验

2019-06-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

国产艾滋病疫苗II期临床试验启动：1500元补助招志愿者

2019-06-15

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

第79届ADA：Dance 501吸入型胰岛素的II期临床结果喜人

2019-06-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色

2019-06-05

科室
- - 订阅+
  - 更多科室
工具
服务